Post-Thrombotic Syndrome: Mechanisms, Drugs and Devices

Mouse Models of Post-Thrombotic Fibrosis

Andrea Obi described mouse studies showing plasmin and MMP activation speed thrombus resolution but also drive venous fibrosis, with monocyte and IL-6 depletion each sparing fibrosis at the cost of impaired thrombus clearance, suggesting a molecular tradeoff underlying post-thrombotic syndrome.

Antithrombotic and Anti-Inflammatory Strategies

Aditya Sharma reviewed evidence for extended low molecular weight heparin, antiplatelet therapy, and statins after iliocaval stenting, arguing inflammation deserves treatment as a fourth pillar alongside anticoagulation given the interplay between coagulation and inflammatory risk factors.

Mechanical Thrombectomy for Acute Iliofemoral Clot

Patrick Mark reviewed the Bashir catheter and mechanical thrombectomy systems including ClotTriever, Indigo, AlphaVac, and Penumbra Lightning, showing wall to wall clot removal with minimal or no lytics and growing CLOUT registry data supporting outpatient intervention.

Horizons in Stenting, Recanalization and Valves

Closing talks covered iliac vein stenting outcomes, femoropopliteal venous recanalization for chronic occlusion, and bioprosthetic venous valve results showing sustained quality of life and reflux gains through 30 months in a first in man study.